Agios (AGIO) Q2 2026 earnings review
Revenue Quadruples on AQVESME Surge, But Pipeline Suffers a Massive Blow
Agios delivered a stunning top-line quarter, with revenue accelerating 259% YoY to $44.7 million, entirely driven by the runaway U.S. success of the AQVESME thalassemia launch. However, this commercial victory was completely overshadowed by a devastating R&D failure: the abrupt discontinuation of the next-generation drug tebapivat across all indications. Management quickly pivoted by spending $25 million to license a new Phase 3-ready asset to plug the pipeline gap. Net loss remained stable at $100.7 million, as the massive revenue influx was absorbed by the new licensing costs and launch expenses.
🐂 Bull Case
The U.S. launch of AQVESME is accelerating rapidly, generating $40.9 million in the quarter. Cumulative prescriptions nearly doubled from 242 in Q1 to 442 in Q2, proving high community demand.
The FDA accepted the sNDA for mitapivat in sickle cell disease with Priority Review, setting up a massive catalyst for November 1, 2026. This unlocks a significantly larger patient population.
🐻 Bear Case
The sudden termination of the tebapivat program in both MDS and sickle cell disease wipes out what management previously touted as a 'best-in-class' future growth pillar.
Despite a $24 million quarter-over-quarter revenue increase, the net loss actually worsened slightly to $100.7 million due to a $25 million licensing payment. Profitability remains distant.
⚖️ Verdict: ⚪
Neutral. The commercial execution on AQVESME is flawless and highly encouraging. However, the complete failure of tebapivat fundamentally damages the long-term enterprise value of the company, forcing a risky, expensive pivot into an external asset.
Key Themes
AQVESME Reaches Escape Velocity
Accelerating. The U.S. commercial launch of AQVESME for thalassemia is proving to be a massive success. U.S. net revenue hit $40.9M, a staggering jump from prior quarters. The number of cumulative prescriptions written by REMS-certified physicians reached 442 by June 30, up from 242 at the end of Q1. This linear growth proves the drug is penetrating well past the initial 'bolus' of highly motivated early adopters.
The Death of the Tebapivat Narrative
Reversing. This is a massive contradiction to prior guidance. Just one quarter ago, management hyped tebapivat as a 'next-generation, more potent' drug designed to sustain the company's long-term growth. Now, it has been completely scrapped. In LR-MDS, it failed to demonstrate clinical benefit. In sickle cell disease, it failed to show a differentiated profile against existing options. This failure erases significant future value and destroys the 'franchise' narrative.
Sickle Cell Catalyst Accelerated
Accelerating. Agios successfully secured an FDA Priority Review for mitapivat in sickle cell disease, with a PDUFA date of November 1, 2026. Simultaneously, they dosed the first patient in the REIGNITE Phase 3 confirmatory trial. A successful approval here opens up a market of approximately 100,000 U.S. patients, significantly larger than the thalassemia and PKD markets combined.
Strategic Pivot: In-Licensing Cevidoplenib
In a direct reaction to the tebapivat failure, Agios spent $25 million upfront to license cevidoplenib from Oscotec. This oral SYK inhibitor targets immune thrombocytopenia (ITP). Management claims it has a $1.0 billion peak U.S. sales potential. However, it requires additional CMC development work and won't enter Phase 3 until 2028, meaning it is years away from generating revenue.
AG-236 Advances as Next Core Innovation
Accelerating. With tebapivat gone, AG-236 (an siRNA targeting TMPRSS6) steps up as the primary internal innovation. Phase 1 results in healthy volunteers demonstrated sustained hepcidin control without the need for titration, suggesting it could be dosed as infrequently as once every six months. Agios is aggressively pushing this into a Phase 2/3 program for polycythemia vera in H2 2026.
R&D Spend Spiking Due to Business Development
Accelerating. R&D expenses jumped to $100.8 million, up from $81.1 million in Q1 and $91.9 million a year ago. This was largely driven by the $25.0 million upfront payment for cevidoplenib. While the company still boasts $964.8 million in cash, the aggressive business development strategy to backfill the pipeline is eating into the profits generated by the AQVESME launch.
Other KPIs
Accelerating. Up from $1.9 million in Q1 and $0.3 million a year ago. This reflects the initial European rollout of PYRUKYND following its May 2026 approval, as well as consistent early demand in the Gulf Cooperation Council (GCC) countries. It proves the international partnership strategy is beginning to bear fruit.
Decelerating. The cash pile dropped below the $1 billion mark for the first time in several quarters, down from $1.16 billion at the end of 2025. Despite the burn, management maintains this provides sufficient runway to fund all planned commercial launches and pipeline expansion.
Guidance
Management provided a long-term target for their newly acquired asset, framing it as a blockbuster opportunity in the ITP space. However, Phase 3 trials do not even begin until H1 2028.
Key Questions
The Tebapivat Autopsy
Tebapivat was previously described as structurally differentiated and more potent. What specifically went wrong in the Phase 2b MDS trial? Was it an issue of toxicity, a failure to elevate hemoglobin sufficiently, or an unexpected drug metabolism issue?
Cevidoplenib Development Costs
With Phase 3 for cevidoplenib delayed until H1 2028 pending 'additional CMC development work,' what are the expected near-term R&D costs associated with getting this asset ready for trials?
AQVESME Conversion Rates
You reported 442 cumulative prescriptions written. What percentage of these have successfully navigated the REMS/payer lag to convert into actively billed patients, and what is the current dropout rate?